These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 18062718)

  • 1. The role of sulodexide in the treatment of diabetic nephropathy.
    Weiss R; Niecestro R; Raz I
    Drugs; 2007; 67(18):2681-96. PubMed ID: 18062718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial.
    Gambaro G; Kinalska I; Oksa A; Pont'uch P; Hertlová M; Olsovsky J; Manitius J; Fedele D; Czekalski S; Perusicová J; Skrha J; Taton J; Grzeszczak W; Crepaldi G
    J Am Soc Nephrol; 2002 Jun; 13(6):1615-25. PubMed ID: 12039991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered.
    Gaddi AV; Cicero AF; Gambaro G
    Int J Nephrol Renovasc Dis; 2010; 3():99-105. PubMed ID: 21694935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy.
    Abaterusso C; Gambaro G
    Treat Endocrinol; 2006; 5(4):211-22. PubMed ID: 16879000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diabetic nephropathy and ACE inhibitors].
    Amann B
    Clin Res Cardiol; 2006 Jan; 95 Suppl 1():i83-7. PubMed ID: 16598556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
    Lambers Heerspink HJ; Fowler MJ; Volgi J; Reutens AT; Klein I; Herskovits TA; Packham DK; Fraser IR; Schwartz SL; Abaterusso C; Lewis J;
    Diabet Med; 2007 Nov; 24(11):1290-5. PubMed ID: 17956455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New potential agents in treating diabetic kidney disease: the fourth act.
    Williams ME
    Drugs; 2006; 66(18):2287-98. PubMed ID: 17181372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARBs vs ACE inhibitors for preventing diabetic nephropathy.
    Greenwood V
    J Fam Pract; 2005 May; 54(5):453; discussion 453-4. PubMed ID: 15865904
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacologic management of diabetic nephropathy.
    Vivian EM; Rubinstein GB
    Clin Ther; 2002 Nov; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria.
    Yongwatana K; Supasyndh O; Satirapoj B
    J Diabetes Res; 2020; 2020():2984680. PubMed ID: 32851094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational drugs for diabetic nephropathy.
    Cortinovis M; Cattaneo D; Perico N; Remuzzi G
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1487-500. PubMed ID: 18808309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One year course of oral sulodexide in the management of diabetic nephropathy.
    Achour A; Kacem M; Dibej K; Skhiri H; Bouraoui S; El May M
    J Nephrol; 2005; 18(5):568-74. PubMed ID: 16299683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].
    Zidek W
    MMW Fortschr Med; 2004 Oct; 146(42):51-2. PubMed ID: 15536706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.